Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Summary
Chlamydia is a common infection among youth and can be given from one person to another during sex. Many people who have chlamydia have no signs of infection at all, but can pass the infection to anyone they have sex with. If not treated, chlamydia can lead to serious health problems. This study will look at how well medicines given for chlamydia infection work. The study requires 306 evaluable subjects, chlamydia-positive, males and non-pregnant females, ages 12-21, living in long-term, gender-segregated youth correctional facilities. Participants will be assigned to receive either doxycycline (2 times per day, by mouth, for 7 days) or azithromycin (1 single dose by mouth). Study procedures will include collection of at least 3 urine samples to test for chlamydia. Study visits will occur during initial enrollment in the study, day 28 after starting treatment, and day 67. Participants will be involved in study related procedures for up to 67 days.
Official title: Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities
Key Details
Gender
All
Age Range
12 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
567
Start Date
2009-12-02
Completion Date
2014-05-27
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Azithromycin
FDA approved, a 1 gm single dose, two 500 mg tablets.
Doxycycline
FDA approved, a 100 mg capsule twice a day for 7 days.
Locations (2)
University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama, United States
Los Angeles County Department of Public Health - Sexually Transmitted Disease Program
Los Angeles, California, United States